KFRX 05
Alternative Names: BK 40195; KFRX-05Latest Information Update: 10 Sep 2024
At a glance
- Originator KeifeRx
- Class Antidementias; Antineoplastics; Antiparkinsonians; Skin disorder therapies; Small molecules
- Mechanism of Action LRRK2 protein modulators; Protein tyrosine kinase inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Preclinical Mastocytosis; Parkinson's disease; Urticaria
Most Recent Events
- 27 Mar 2024 Preclinical trials in Mastocytosis in USA (PO), prior to March 2024
- 27 Mar 2024 Preclinical trials in Parkinson's disease in USA (PO), prior to March 2024
- 27 Mar 2024 Preclinical trials in Urticaria in USA (PO), prior to March 2024